索内洛基马布,一种IL-17A/IL-17F抑制活性牛皮关节炎的纳米体:一个随机的,安慰剂控制的第二阶段试验
Iain B McInnes1, Laura C Coates2, Philip J Mease3
1College of Medical Veterinary & Life Sciences (MVLS), University of Glasgow, Glasgow, UK. iain.mcinnes@glasgow.ac.uk.
Nature medicine
|October 6, 2025
概括
在第二阶段试验中,sonelokimab (SLK) 显著改善了牛皮关节炎 (PsA) 症状,在ACR50和PASI90终点表现出有效性. 治疗耐受性很好,显示PsA管理的希望.
科学领域:
- 风湿病学和免疫学
- 临床药理学 临床药理学
- 皮肤病学 皮肤病学
背景情况:
- 牛皮关节炎 (PsA) 是一种慢性,炎症性疾病,影响生活质量.
- 介质蛋白-17 (IL-17) 在PsA病变发生过程中起着关键作用.
- 向IL-17A和IL-17F提供了一个潜在的治疗策略.
研究的目的:
- 评估Sonelokimab (SLK) 作为IL-17A/F抑制剂的疗效和安全性,用于患有活跃PSA的患者.
- 评估SLK对疾病活动和患者报告结果的影响.
主要方法:
- 第2阶段,随机,双盲,安慰剂对照试验,涉及207名患有活跃PSA的患者.
- 患者每4周接受60毫克或120毫克的sonelokimab (SLK) (带或不带诱导),安慰剂或阿达利木马布.
- 主要终点:美国风湿病学学院 (ACR) 在第12周的50反应.
主要成果:
- 60毫克和120毫克的SLK (带诱导) 满足了主要终点,在第12周实现了ACR50 (46.3%和46.5%与安慰剂的20.0%相比).
- 对于两种SLK剂量来说,在第12周观察到ACR20和牛皮区域和严重性指数 (PASI) 90显著改善.
- 到第24周,多达61%的SLK患者实现了像最小疾病活性这样的高值终点.
- 一般来说,SLK耐受性很好,常见的不良事件包括鼻炎和上呼吸道感染.
结论:
- 索内洛基马布在改善活跃牛皮关节炎的迹象和症状方面表现出显著的疗效.
- SLK为PsA患者提供了一个有前途的治疗选择,解决了多种疾病领域.
- 斯莱克的安全概况与它的作用机制一致.
相关概念视频
T Cell Types and Functions
3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692


